Immunosuppression in pregnant women with systemic lupus erythematosus

Expert Review of Clinical Immunology

Volumn 11, Issue 5, 2015, Pages 549-552

  Ponticelli, Claudio ^a   Moroni, Gabriella ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Autoimmune diseases; Immunosuppression; Lupus nephritis; Pregnancy; Systemic lupus erythematosus; Teratogenic drugs

Indexed keywords

AZATHIOPRINE; BELIMUMAB; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; TERATOGENIC AGENT; ISOXAZOLE DERIVATIVE; MYCOPHENOLATE MOFETIL;

ADULTHOOD; ADVERSE OUTCOME; BLOOD PRESSURE REGULATION; CANCER RISK; CHROMOSOME DAMAGE; CHRONIC KIDNEY FAILURE; CONCEPTION; DRUG EFFICACY; FETUS MALFORMATION; FETUS RISK; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LACTATION; LOW BIRTH WEIGHT; LUPUS ERYTHEMATOSUS NEPHRITIS; MUTAGENICITY; NONHUMAN; PATIENT COUNSELING; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURITY; PROGNOSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CONTRAINDICATIONS; ENVIRONMENTAL EXPOSURE; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRE-ECLAMPSIA; PREGNANCY COMPLICATIONS; TREATMENT WITHDRAWAL;

CYCLOSPORINE; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPERTENSION; IMMUNOSUPPRESSION; ISOXAZOLES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MATERNAL EXPOSURE; MYCOPHENOLIC ACID; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; WITHHOLDING TREATMENT;

EID: 84928196268     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1033404     Document Type: Review

References (20)

1. Chambers CD, Tutuncu ZM, Johnson D, et al. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 2006;8:215-51
2. Bay Bjørn AM, Ehrenstein V, Hundborg HH, et al. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther 2014;21:73-80
3. Kurtoglu S, Sarc D, Akn MA, et al. Fetal adrenal suppression due to maternal corticosteroid use: case report. J Clin Res Pediatr Endocrinol 2011;3:160-2
4. Bloom SL, Sheffield JS, McIntire DD, et al. Antenatal dexamethasone and decreased birth weight. Obstet Gynecol 2001;97: 485-90
5. Lannes G, Elias FR, Cunha B, et al. Successful pregnancy after cyclophosphamide therapy for lupus nephritis. Arch Gynecol Obstet 2011; 283(Suppl 1):61-5
6. Comish PB, Drumond AL, Kinnell HL, et al. Fetal cyclophosphamide exposure induces testicular cancer and reduced spermatogenesis and ovarian follicle numbers in mice. PLoS One 2014;9:e93311
7. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007;79: 696-701
8. Hoeltzenbein M, Elefant E, Vial T, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the european network of teratology information services. Am J Med Genet A 2012;158A:588-96
9. McKay DB, Josephson MA. Pregnancies in recipients of solid organs. N Engl J Med 2006;354:1281-93
10. Chambers CD, Tutunku ZM, Johnson D, et al. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 2006;8:215-25
11. Hou S. Pregnancy in renal transplant recipients. Adv Chronic Kidney Dis 2013;20:253-9
12. Tendron-Franzin A, Gouyon JB, Guignard JP, et al. Long-term effects of in utero exposure to cyclosporin A on renal function in the rabbit. J Am Soc Nephrol 2004;15:2687-93
13. Cochat P, Decramer S, Robert-Gnansia E, et al. Renal outcome of children exposed to cyclosporine in utero. Transplant Proc 2004;36(2 Suppl):208S-10S
14. Diav-Citrin O, Blyakhman S, Shechtman S, et al. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol 2013;39:58-62
15. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Roantibody-associated cardiac manifestations of neonatal lupus. Circulation 2012;126:76-82
16. Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001;63:106-12
17. Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012;64:2085-94
18. Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology 1998;57:51-5
19. Ojeda-Uribe M, Afif N, Dahan E, et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 2013;32(5):695-700
20. Constantinescu S, Pai A, Coscia LA, et al. Breast-feeding after transplantation. Best Pract Res Clin Obstet Gynaecol 2014;28: 1163-73